Cargando…
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023986/ https://www.ncbi.nlm.nih.gov/pubmed/33026092 http://dx.doi.org/10.1093/rheumatology/keaa612 |
| _version_ | 1783675217586946048 |
|---|---|
| author | Bechman, Katie Oke, Anuoluwapo Yates, Mark Norton, Sam Dennison, Elaine Cope, Andrew P Galloway, James B |
| author_facet | Bechman, Katie Oke, Anuoluwapo Yates, Mark Norton, Sam Dennison, Elaine Cope, Andrew P Galloway, James B |
| author_sort | Bechman, Katie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8023986 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80239862021-04-13 Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register Bechman, Katie Oke, Anuoluwapo Yates, Mark Norton, Sam Dennison, Elaine Cope, Andrew P Galloway, James B Rheumatology (Oxford) Corrigendum Oxford University Press 2020-10-07 /pmc/articles/PMC8023986/ /pubmed/33026092 http://dx.doi.org/10.1093/rheumatology/keaa612 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigendum Bechman, Katie Oke, Anuoluwapo Yates, Mark Norton, Sam Dennison, Elaine Cope, Andrew P Galloway, James B Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register |
| title | Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register |
| title_full | Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register |
| title_fullStr | Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register |
| title_full_unstemmed | Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register |
| title_short | Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register |
| title_sort | corrigendum to: is background methotrexate advantageous in extending tnf inhibitor drug survival in elderly patients with rheumatoid arthritis? an analysis of the british society for rheumatology biologics register |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023986/ https://www.ncbi.nlm.nih.gov/pubmed/33026092 http://dx.doi.org/10.1093/rheumatology/keaa612 |
| work_keys_str_mv | AT bechmankatie corrigendumtoisbackgroundmethotrexateadvantageousinextendingtnfinhibitordrugsurvivalinelderlypatientswithrheumatoidarthritisananalysisofthebritishsocietyforrheumatologybiologicsregister AT okeanuoluwapo corrigendumtoisbackgroundmethotrexateadvantageousinextendingtnfinhibitordrugsurvivalinelderlypatientswithrheumatoidarthritisananalysisofthebritishsocietyforrheumatologybiologicsregister AT yatesmark corrigendumtoisbackgroundmethotrexateadvantageousinextendingtnfinhibitordrugsurvivalinelderlypatientswithrheumatoidarthritisananalysisofthebritishsocietyforrheumatologybiologicsregister AT nortonsam corrigendumtoisbackgroundmethotrexateadvantageousinextendingtnfinhibitordrugsurvivalinelderlypatientswithrheumatoidarthritisananalysisofthebritishsocietyforrheumatologybiologicsregister AT dennisonelaine corrigendumtoisbackgroundmethotrexateadvantageousinextendingtnfinhibitordrugsurvivalinelderlypatientswithrheumatoidarthritisananalysisofthebritishsocietyforrheumatologybiologicsregister AT copeandrewp corrigendumtoisbackgroundmethotrexateadvantageousinextendingtnfinhibitordrugsurvivalinelderlypatientswithrheumatoidarthritisananalysisofthebritishsocietyforrheumatologybiologicsregister AT gallowayjamesb corrigendumtoisbackgroundmethotrexateadvantageousinextendingtnfinhibitordrugsurvivalinelderlypatientswithrheumatoidarthritisananalysisofthebritishsocietyforrheumatologybiologicsregister |